All In Biotech

Drug Trial Radar · NCT06101823

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Nov 21, 2023

Primary completion

Sep 3, 2024

Study completion Aug 18, 2025

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.

Conditions

  • Atopic Dermatitis

Interventions

  • OpSCFBiological

    Administered SC.

  • PlaceboBiological

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16Time frame: Baseline, Week 16

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center

    Birmingham, Alabama

  • First OC Dermatology Research

    Fountain Valley, California

  • Axon Clinical Research

    Inglewood, California

  • University Clinical Trials

    San Diego, California

  • Unison Clinical Trials

    Sherman Oaks, California

  • Skin Care Research

    Boca Raton, Florida

  • Skin Research of South Florida

    Miami, Florida

  • RM Medical Research

    Miami Lakes, Florida

  • Advanced Clinical Research Institute

    Tampa, Florida

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Options Research Group

    West Lafayette, Indiana

  • DS Research of Kentucky

    Louisville, Kentucky

  • Oakland Hills Dermatology P.C

    Auburn Hills, Michigan

  • Saginaw Bay Dermatology

    Bay City, Michigan

  • Skin Cancer and Dermatology Institute

    Reno, Nevada

  • Forest Hills Dermatology Group

    Kew Gardens, New York

  • Rodgers Dermatology

    Frisco, Texas

  • Dermatology Of Seattle

    Bellevue, Washington

  • Oshawa Clinic Dermatology Trials

    Oshawa, Ontario, Canada

  • Research Toronto

    Toronto, Ontario, Canada

  • Innovaderm Research Inc

    Montreal, Quebec, Canada

  • Centre de Recherche Saint-Louis

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.